Ethinylestradiol/Chlormadinone acetate dermatological benefits

American Journal of Clinical Dermatology

Volumn 12, Issue SUPPL. 1, 2011, Pages 3-11

  Guerra Tapia, Aurora ^a   Pérez, Blanca Sancho ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; PLACEBO;

ACNE VULGARIS; ANDROGEN BLOOD LEVEL; BREAST TENDERNESS; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HAIR LOSS; HEADACHE; HIRSUTISM; HUMAN; MIGRAINE; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEBORRHEA; SKIN MANIFESTATION; SOCIAL ASPECT;

EID: 80052433016     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/1153874-S0-000000000-00000     Document Type: Review

References (41)

1. Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives. Treat Endocrinol 2002; 1 (6): 372-386
2. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000 Aug; 21 (4): 363-392 (Pubitemid 32279645)
3. Rivera R, Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr 2009 Jan-Feb; 100 (1): 33-37
4. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007 Apr; 56 (4): 651-663 (Pubitemid 46400177)
5. Van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol 2004; 5 (6): 435-441 (Pubitemid 40175261)
6. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 2004 May; 19 (5): 1039-1042 (Pubitemid 38618475)
7. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older [published erratum appears in J Am Acad Dermatol 2008 May; 58 (5): 874]. J Am Acad Dermatol 2008 Jan; 58 (1): 56-59 (Pubitemid 350298137)
8. Hanna S, Sharma J, Klotz J. Acne vulgaris: more than skin deep [abstract]. Dermatol Online J 2003 Aug; 9 (3): 8
9. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999 Apr; 140 (4): 672-676 (Pubitemid 29191387)
10. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999 Feb; 140 (2): 273-282 (Pubitemid 29111356)
11. Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996 Nov; 66 (5): 734-740 (Pubitemid 26357573)
12. Alsantali A, Shapiro J. Management of hirsutism. Skin Therapy Lett 2009 Sep; 14 (7): 1-3
13. Sonino N, Fava GA, Mani E, et al. Quality of life of hirsute women. Postgrad Med J 1993 Mar; 69 (809): 186-189 (Pubitemid 23094646)
14. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001 Jan; 27 (1): 53-54 (Pubitemid 32107618)
15. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999 Sep; 141 (3): 398-405 (Pubitemid 29448398)
16. Rivera R, Guerra-Tapia A. Management of androgenetic alopecia in postmenopausal women. Actas Dermosifiliogr 2008 May; 99 (4): 257-261 (Pubitemid 351729642)
17. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician 2000 May 1; 61 (9): 2703-10, 13-4 (Pubitemid 30337558)
18. Elewski BE. Safe and effective treatment of seborrheic dermatitis. Cutis 2009
19. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006 Jul 1; 74 (1): 125-130 (Pubitemid 44049740)
20. Zouboulis CC, Xia L, Akamatsu H, et al. The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 1998; 196 (1): 21-31 (Pubitemid 28116033)
21. Sancho B, Guerra-Tapia A. Oral contraceptives in dermatology. Actas Dermosifiliogr 2009 Jul-Aug; 100 (6): 445-455
22. Givens JR, Andersen RN, Wiser WL, et al. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab 1974 May; 38 (5): 727-735
23. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 2002; 3 (8): 571-578 (Pubitemid 35252507)
24. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a singleblind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38-44 (Pubitemid 32830529)
25. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 2003 Apr; 67 (4): 305-312 (Pubitemid 36398516)
26. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03 mg (Belara). Clin Drug Investig 2002; 22 (4): 221-231
27. Curran MP, Wagstaff AJ. Ethinylestradiol/chlormadinone acetate. Drugs 2004; 64 (7): 751-760; discussion 61-2 (Pubitemid 38471374)
28. Grünenthal GmbH. Belara®: highlight of the products properties (product monograph) [online]. Available from URL: http://www.grunenthal.com/cms/ cda/-common/inc/display-file.jsp?fileID=85500520 [Accessed 2010 Aug 3].
29. Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg andCMA2mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009 Jul; 80 (1): 25-33
30. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 1): 1263-1269
31. Saunders DM, Marcus SL, Saxena BB, et al. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle. Fertil Steril 1971 May; 22 (5): 332-344
32. Larsson-Cohn U, Johansson ED, Wide L, et al. Effects of continuous daily administration of 0.5mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol (Copenh) 1970 Apr; 63 (4): 705-716
33. Kreitmann B, Bugat R, Bayard F. Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. J Clin Endocrinol Metab 1979 Dec; 49 (6): 926-929 (Pubitemid 10171341)
34. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998 Feb; 57 (2): 103-109 (Pubitemid 28208481)
35. Zahradnik HP. Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 2005; 10 Suppl. 1: 12-18 (Pubitemid 41790962)
36. Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008 Dec; 24 (12): 718-723
37. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based phase III study. Contraception 2008 May; 77 (5): 337-343
38. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211-220
39. Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007 Nov; 76 (5): 342-347 (Pubitemid 47600123)
40. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 2007 Aug; 76 (2): 84-90 (Pubitemid 47080979)
41. Kerscher M, Reuther T, Bayrhammer J, et al. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28 (11): 703-711